For US veterans with diabetes and substance use issues, taking GLP-1 drugs (like Ozempic) might lower their chances of ending up in the ER, being hospitalized, or dying from substance-related...

For US veterans with type 2 diabetes and a history of substance use, starting a GLP-1 drug (like Ozempic) may lower their chances of overdosing on drugs or having suicidal thoughts compared to starting a different diabetes drug called an SGLT-2 inhibitor.

For US veterans with type 2 diabetes, starting a GLP-1 drug (like Ozempic) might help lower the chance of developing addiction problems—like with alcohol, drugs, or smoking—over three years compared to starting a different diabetes drug called an SGLT-2 inhibitor.

For US veterans with type 2 diabetes, taking GLP-1 drugs might help lower the chance of getting hooked on opioids over three years compared to another diabetes drug, SGLT-2 inhibitors — about 1 fewer case for every 1,000 people.

Among adults with type 2 diabetes starting injectable treatment, those using GLP-1 receptor agonists had a lower risk of heart attack, stroke, or death over two years compared to those using basal insulin, based on statistical analysis of patient data.

Among adults with type 2 diabetes and advanced kidney disease, starting treatment with an SGLT2 inhibitor carries the same risk of serious heart problems or death as starting treatment with a GLP-1 receptor agonist.